Cologuard® revenue increased 78 percent to $103 million during second quarter
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Exact Sciences (EXAS) PT Lowered to $65 at Cowen; Buy on Weakness
August 2, 2018 7:56 AM EDTCowen lowered its price target on Exact Sciences (NASDAQ: EXAS) to $65.00 (from $85.00) while maintaining a Outperform rating following Q2 miss.
Analyst Doug Schenkel commented, "EXAS missed Q2 revenue and volume expectations. While we think this could have been better explained, further... More
Exact Sciences (EXAS) Tops Q2 EPS by 3c, Revs Miss; Maintains Outlook
August 1, 2018 4:09 PM EDTExact Sciences (NASDAQ: EXAS) reported Q2 EPS of ($0.30), $0.03 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $102.9 million versus the consensus estimate of $104.66 million.
GUIDANCE:
Exact Sciences sees FY2018 revenue of $420-430 million, versus the consensus... More
